Barclays’s United Therapeutics UTHR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-33,500
| Closed | -$5.6M | – | 5091 |
|
|
2021
Q1 | $5.6M | Buy |
+33,500
| New | +$5.59M | ﹤0.01% | 1425 |
|
|
2020
Q2 | – | Sell |
-38,900
| Closed | -$3.69M | – | 6277 |
|
|
2020
Q1 | $3.69M | Buy |
38,900
+27,600
| +244% | +$2.62M | ﹤0.01% | 1728 |
|
|
2019
Q4 | $995K | Buy |
11,300
+9,600
| +565% | +$845K | ﹤0.01% | 3683 |
|
|
2019
Q3 | $136K | Sell |
1,700
-1,700
| -50% | -$137K | ﹤0.01% | 5246 |
|
|
2019
Q2 | $265K | Sell |
3,400
-39,800
| -92% | -$3.72M | ﹤0.01% | 4859 |
|
|
2019
Q1 | $5.07M | Buy |
43,200
+42,400
| +5,300% | +$4.94M | ﹤0.01% | 1660 |
|
|
2018
Q4 | $87K | Sell |
800
-10,500
| -93% | -$1.22M | ﹤0.01% | 5141 |
|
|
2018
Q3 | $1.45M | Buy |
11,300
+300
| +3% | +$37.1K | ﹤0.01% | 3268 |
|
|
2018
Q2 | $1.25M | Sell |
11,000
-18,400
| -63% | -$2.02M | ﹤0.01% | 3046 |
|
|
2018
Q1 | $3.3M | Buy |
29,400
+27,900
| +1,860% | +$3.54M | ﹤0.01% | 1970 |
|
|
2017
Q4 | $222K | Sell |
1,500
-47,400
| -97% | -$6.03M | ﹤0.01% | 4592 |
|
|
2017
Q3 | $5.73M | Buy |
48,900
+13,900
| +40% | +$1.78M | 0.01% | 1431 |
|
|
2017
Q2 | $4.54M | Buy |
35,000
+31,100
| +797% | +$3.88M | ﹤0.01% | 1548 |
|
|
2017
Q1 | $528K | Sell |
3,900
-6,800
| -64% | -$1.03M | ﹤0.01% | 3351 |
|
|
2016
Q4 | $1.53M | Buy |
10,700
+800
| +8% | +$102K | ﹤0.01% | 2353 |
|
|
2016
Q3 | $1.17M | Buy |
9,900
+4,300
| +77% | +$517K | ﹤0.01% | 2488 |
|
|
2016
Q2 | $593K | Buy |
5,600
+200
| +4% | +$22.3K | ﹤0.01% | 3063 |
|
|
2016
Q1 | $599K | Buy |
5,400
+1,200
| +29% | +$152K | ﹤0.01% | 2995 |
|
|
2015
Q4 | $655K | Sell |
4,200
-3,300
| -44% | -$480K | ﹤0.01% | 2978 |
|
|
2015
Q3 | $983K | Buy |
7,500
+1,300
| +21% | +$209K | ﹤0.01% | 2731 |
|
|
2015
Q2 | $1.07M | Sell |
6,200
-8,800
| -59% | -$1.58M | ﹤0.01% | 2827 |
|
|
2015
Q1 | $2.58M | Sell |
15,000
-3,100
| -17% | -$473K | ﹤0.01% | 2076 |
|
|
2014
Q4 | $2.33M | Sell |
18,100
-19,600
| -52% | -$2.53M | ﹤0.01% | 2390 |
|
|
2014
Q3 | $4.83M | Buy |
37,700
+22,100
| +142% | +$2.28M | ﹤0.01% | 1810 |
|
|
2014
Q2 | $1.37M | Buy |
15,600
+14,300
| +1,100% | +$1.38M | ﹤0.01% | 3014 |
|
|
2014
Q1 | $122K | Sell |
1,300
-100
| -7% | -$10.2K | ﹤0.01% | 5268 |
|
|
2013
Q4 | $158K | Sell |
1,400
-9,300
| -87% | -$839K | ﹤0.01% | 5231 |
|
|
2013
Q3 | $835K | Sell |
10,700
-40,800
| -79% | -$2.98M | ﹤0.01% | 3558 |
|
|
2013
Q2 | $3.39M | Buy |
+51,500
| New | +$3.32M | ﹤0.01% | 1976 |
|
Other funds holding UTHR
ACA
VPM
VCM
Barclays's UTHR Position: Q1 2026 in Review
Barclays reduced its United Therapeutics (UTHR) stake by 31% in Q1 2026, selling an estimated $13.9M and leaving 63,005 shares worth $37.4M. The position accounts for 0.01% of the portfolio, ranked #837.
Barclays first reported a position in UTHR in Q2 2013 and has held it in 52 quarters since. The position peaked at $47.3M in Q3 2025. 851 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.
- Barclays held 63,005 shares of United Therapeutics worth $37.4M as of Q1 2026.
- Barclays sold 27,920 United Therapeutics shares in Q1 2026, an estimated $13.9M.
- United Therapeutics made up 0.01% of Barclays's portfolio in Q1 2026, its #837 holding.
- Barclays first reported a position in United Therapeutics in Q2 2013 and has held it in 52 quarters since.
- Barclays's United Therapeutics position peaked at $47.3M in Q3 2025.
- 851 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.